An open-label, randomized phase III trial of cisplatin and 5-fluorouracil with or without panitumumab for patients with nonresectable, advanced or metastatic esophageal squamous cell cancer

Mise à jour : Il y a 4 ans
Référence : EUCTR2010-020606-15

Femme et Homme

  • | Pays :
  • -
  • | Organes :
  • -
  • | Spécialités :
  • -

Extrait

To demonstrate superiority of 5-fluorouracil, cisplatin and panitumumab over 5-fluorouracil and cisplatin alone in terms of overall survival in esophageal cancer


Critère d'inclusion

  • Patients with nonresectable, advanced or metastatic esophageal squamous cell cancer (ESCC)